JAK3 and hepatocellular carcinoma: In September 2023, EMA approved Ritlecitinib, an oral inhibitor of JAK3 and tyrosine kinase expressed in the hepatocellular carcinoma family (TEC), for the treatment of severe AA in adults as well as in adolescents aged 12 years and older [27].